Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alentis Therapeutics AG
NCT07439939 · Liver Cirrhosis, Portal Hypertension
NCT06680583 · Liver Cirrhosis, Gastrointestinal Bleeding
NCT07437755 · Liver Cirrhosis With Acute Decompensation
NCT06169592 · Liver Cirrhosis, Liver Transplant; Complications
NCT07275554 · HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis, and more
American Research Corporation
San Antonio, Texas
APEX GmbH
Munich
ARENSIA Exploratory Medicine S.R.L.
Bucharest
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions